

# **Molecular Diagnostics**

## **Part I: Technologies & Applications**

**by**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His books include "Role of Nanobiotechnology in Molecular Diagnostics" (2006), "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011; 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese edition 2012; 2<sup>nd</sup> ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed Chemical Industry Press 2016, 2<sup>nd</sup> ed 2017), "Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011)", "Applications of Biotechnology in Neurology (Springer, 2013)", and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

## **A B O U T   T H I S   R E P O R T**

Prof. Jain wrote the first commercial report on DNA Diagnostics in 1995, which was published by PJB Publication, London. This was updated in 1997 as Molecular Diagnostics I and the next edition, Molecular Diagnostics II, was published in 1999 – both by Decision Resources Inc, USA. All the three versions of the reports were well accepted and sold widely. The current version was originally published by Jain PharmaBiotech in 2001 and is constantly updated and revised since then. Not only was this the first such report on molecular diagnostics, it is the longest continuously published report on this topic (20 years). It is also the most comprehensive and detailed report on this topic containing profiles of the largest number of companies involved in molecular diagnostics.

**November 2017 (continuously published since 1995)**  
**Copyright © 2017 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:       +4161-6924461**  
**Email:            info@pharmabiotech.ch**  
**Web site:         http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>25</b>
<b>1. Introduction .....</b>	<b>27</b>
<b>Definitions and scope of the subject .....</b>	<b>27</b>
<b>Historical evolution of molecular diagnostics.....</b>	<b>27</b>
<b>Molecular biology relevant to molecular diagnostics.....</b>	<b>28</b>
DNA .....	28
<i>DNA polymerases.....</i>	28
<i>Restriction endonucleases.....</i>	29
RNA .....	29
<i>RNA polymerases.....</i>	29
<i>Non-coding RNAs.....</i>	30
DNA transcription.....	30
Chromosomes .....	30
<i>Chromatin.....</i>	31
Telomeres.....	31
Mitochondrial DNA .....	31
Genes.....	32
<i>The genetic code.....</i>	32
<i>Gene expression .....</i>	32
The human genome .....	33
<i>ENCODE .....</i>	33
Variations in the human genome.....	34
<i>Variations in DNA sequences .....</i>	34
<i>Single nucleotide polymorphisms .....</i>	35
Haplotyping.....	35
<i>Copy number variations in the human genome.....</i>	36
<i>Genotype and haplotypes.....</i>	37
<i>Insertions and deletions in the human genome.....</i>	37
<i>Complex chromosomal rearrangements .....</i>	38
<i>Large scale variation in human genome .....</i>	39
<i>Structural variations in the human genome .....</i>	39
<i>Replication of the DNA helix .....</i>	39
<i>Transposons.....</i>	40
Epigenetics/epigenomics .....	40
<i>DNA methylation.....</i>	40
Proteins .....	41
Proteomics.....	41
Monoclonal antibodies .....	42
Aptamers.....	42
<b>Basics of molecular diagnostics .....</b>	<b>42</b>
Tracking DNA: the Southern blot .....	43
Pulsed-field gel electrophoresis.....	43
DNA Probes.....	43
The polymerase chain reaction .....	44
<i>Basic Principles of PCR.....</i>	44
<i>Target selection .....</i>	44
<i>Detection of amplified DNA.....</i>	45
<b>Impact of human genome project on molecular diagnostics .....</b>	<b>45</b>
<i>Mapping and sequencing of structural variation from human genomes.....</i>	46
1000 Genomes Project .....	46
<i>Human Variome Project.....</i>	47
<b>Role of bioinformatics in molecular diagnostics.....</b>	<b>48</b>
<b>Systems biology approach to molecular diagnostics .....</b>	<b>48</b>
<b>Synthetic biology and molecular diagnostics .....</b>	<b>49</b>
<b>Biomarkers .....</b>	<b>49</b>
<b>Applications of molecular diagnostics.....</b>	<b>50</b>
<b>2. Molecular Diagnostic Technologies .....</b>	<b>53</b>
<b>Introduction .....</b>	<b>53</b>
<b>DNA sample collection and extraction.....</b>	<b>53</b>
Blood samples .....	53
Buccal swabs and saliva.....	53
Dried blood spots.....	54
Formalin-fixed, paraffin-embedded tissues .....	54
Manual vs automated DNA extraction .....	55

Urine samples for transrenal DNA .....	55
<b>Sample preparation .....</b>	<b>56</b>
Pressure Cycling Technology .....	56
<b>Membrane immobilization of nucleic acids.....</b>	<b>56</b>
<b>Automation of sample preparation in molecular diagnostics.....</b>	<b>57</b>
ABI PRISM 6700 Automated Nucleic Acid Workstation .....	57
BioRobot technology.....	57
COBAS AmpliPrep System.....	57
GENESIS FE500 Workcell .....	57
GeneMole.....	58
PCR BioCube .....	58
QIASymphony.....	58
Tigris instrument system .....	58
Techniques for sample preparation suitable for automation .....	59
<i>Xtra Amp Genomic DNA Extraction</i> .....	59
<i>Extraction of DNA from paraffin sections</i> .....	59
<i>Dynabead technology</i> .....	59
<i>SamPrep</i> .....	60
Use of magnetic particles for automation in genome analysis .....	60
Companies involved in nucleic acid isolation .....	60
<b>Labeling and detection of nucleic acids.....</b>	<b>62</b>
<b>Novel PCR methods.....</b>	<b>62</b>
Addressing limitations of PCR .....	62
Cooperative primer .....	62
ARMS-PCR .....	63
CAST-PCR .....	63
Combined PCR-ELISA .....	63
Convection PCR .....	64
Digital PCR.....	64
Dumbbell PCR .....	65
Emulsion PCR.....	65
ExCyto PCR.....	66
Fast PCR.....	66
Immuno PCR.....	66
Long and accurate PCR.....	67
Multiplex PCR .....	67
Overlap extension PCR .....	67
Real-time PCR systems.....	67
<i>Dyes used in real-time PCR</i> .....	68
<i>Target-specific fluorogenic probes for monitoring real-time PCR</i> .....	69
<i>Applications of real-time PCR</i> .....	69
<i>Limitations of real-time PCR</i> .....	70
<i>Quantitative PCR for accurate low level DNA analysis</i> .....	70
<i>qPCR for quantification of mtDNA</i> .....	70
<i>Real-time qPCR for measuring the length of telomeres</i> .....	71
<i>Guidelines for real-time qPCR</i> .....	71
<i>Future applications of real-time qPCR</i> .....	71
Commercially available real-time PCR systems .....	72
<i>Life Technologies' Real-Time PCR systems</i> .....	72
<i>LightCycler PCR system</i> .....	73
<i>LightUp probes based on real-time PCR</i> .....	73
<i>MNAzyme qPCR</i> .....	74
<i>READ™ real-time PCR method</i> .....	75
<i>StellARray™ technology</i> .....	75
Reverse hybridization PCR assays .....	75
Reverse transcriptase (RT)-PCR.....	75
<i>Standardized reverse transcriptase PCR</i> .....	76
Single cell PCR.....	77
<i>LATE-PCR</i> .....	77
<i>COLD-PCR</i> .....	77
<i>AmpliGrid-System</i> .....	78
Solar thermal PCR system monitored by Smartphone .....	78
Ultrafast photonic PCR.....	79
<b>DNA melt analysis.....</b>	<b>79</b>
High-resolution DNA melt analysis for genotyping .....	79
PCR device for DNA melt analysis in space .....	80
<b>Monitoring of gene amplification in molecular diagnostics .....</b>	<b>80</b>
<b>Non-PCR nucleic acid amplification methods .....</b>	<b>80</b>
DNA probes with conjugated minor groove binder .....	80
DNABLE.....	81

Dynamic Flux Amplification .....	81
Isothermal nucleic acid amplifications .....	81
<i>Isothermal reaction for amplification of oligonucleotides</i> .....	81
<i>Isothermal and chimeric primer-initiated amplification of nucleic acids</i> .....	82
<i>Loop-mediated amplification</i> .....	82
<i>Single Primer Isothermal Amplification</i> .....	82
<i>Strand Invasion Based Amplification</i> .....	83
Linked Linear Amplification.....	83
Multiplex Ligation-Dependent Probe Amplification .....	83
Rapid analysis of gene expression .....	83
Recombinase polymerase amplification .....	84
Rolling circle amplification technology.....	84
<i>Gene-based diagnostics through RCAT</i> .....	85
<i>RCAT-immunodiagnosics</i> .....	86
<i>RCAT-pharmacogenomics</i> .....	86
<i>Circle-to-circle amplification</i> .....	86
Ramification amplification method.....	86
Transcription mediated amplification .....	87
WAVE nucleic acid fragment analysis system .....	87
<b>Technologies for signal amplification</b> .....	<b>88</b>
3 DNA dendrimer signal amplification .....	88
Hybridization signal amplification method .....	89
Signal mediated amplification of RNA technology .....	90
Invader assays .....	91
Hybrid Capture technology .....	92
Branched DNA test.....	93
Tyramide signal amplification .....	93
Non-enzymatic signal amplification technologies .....	93
<b>Non-PCR methods for molecular diagnosis</b> .....	<b>94</b>
Direct molecular analysis without amplification .....	95
<i>Trilogy™ Platform</i> .....	95
<i>Direct detection of dsDNA</i> .....	96
<b>Multiplex assays</b> .....	<b>96</b>
<b>Fluorescent in situ hybridization</b> .....	<b>96</b>
FISH technique .....	97
Applications of FISH .....	98
Modifications of FISH.....	99
Direct visual in situ hybridization .....	99
Direct labeled Satellite FISH probes.....	99
Comparative genomic hybridization .....	99
Primed in situ labeling .....	100
Interphase FISH .....	100
FISH with telomere-specific probes .....	100
Multicolor FISH .....	101
<i>Simultaneous Ultrasensitive Subpopulation staining/Hybridization In situ</i> .....	101
Automation of FISH.....	101
Companies involved in FISH diagnostics.....	102
<b>RNA diagnostics</b> .....	<b>102</b>
RNA isolation from tissue samples.....	103
Commercially available tests for mRNA detection and quantitation .....	103
Branched-chain DNA assay for measurement of RNA .....	104
Cycling probe technology .....	104
Invader RNA assays .....	104
Linear RNA amplification .....	105
Non-isotopic RNase cleavage assay .....	105
Nucleic acid sequence-based amplification .....	105
Q Beta replicase system .....	108
RNAScope.....	108
RNA expression profiling .....	108
<i>Visualization of mRNA expression in vivo</i> .....	108
Solid Phase Transcription Chain Reaction .....	109
Transcriptome analysis .....	109
MicroRNA diagnostics .....	109
<i>Microarray vs quantitative PCR for measuring miRNAs</i> .....	110
<i>Microarrays for analysis of miRNA gene expression</i> .....	110
<i>miR-TRAP to identify miRNA targets in vivo</i> .....	111
<i>Modification of in situ hybridization for detection of miRNAs</i> .....	111
<i>Nuclease Protection Assay to measure miRNA expression</i> .....	112
<i>Real-time PCR for expression profiling of miRNAs</i> .....	112
<i>Use of LNA to explore miRNA</i> .....	112

<b>Whole genome amplification.....</b>	<b>113</b>
Companies that provide technologies for whole genome amplification .....	113
<i>QIAGEN's Repli-G system.....</i>	<i>113</i>
<i>GenomePlex™ Whole Genome Amplification .....</i>	<i>114</i>
<b>DNA sequencing.....</b>	<b>114</b>
Applications of next generation sequencing in molecular diagnostics .....	115
Companies developing sequencing for molecular diagnostics .....	116
Molecular diagnostics and sequencing in space .....	117
<b>Genome-wide approach for chromatin mapping .....</b>	<b>118</b>
<b>Mitochondrial sequencing .....</b>	<b>119</b>
Identification of unknown DNA sequences .....	119
<i>Mitochondrial exome sequencing.....</i>	<i>120</i>
<b>Optical mapping.....</b>	<b>120</b>
<b>Gene expression analysis.....</b>	<b>120</b>
Gene expression profiling on whole blood samples .....	121
Gene expression patterns of white blood cells.....	122
Gene expression profiling based on alternative RNA splicing .....	122
MAUI (MicroArray User Interface) hybridization .....	123
Monitoring in vivo gene expression by molecular imaging .....	123
Serial analysis of gene expression (SAGE).....	123
Single-cell gene expression analysis .....	123
T cell receptor expression analysis .....	125
Tangerine™ expression profiling .....	125
Whole genome expression array .....	125
Ziplex™ system .....	126
Companies involved in gene expression analysis.....	126
<b>Peptide nucleic acid technology.....</b>	<b>127</b>
Use of PNA with fluorescence in situ hybridization .....	128
PNA and PCR .....	129
Use of PNA with biosensors .....	129
PNA-based PD-loop technology .....	130
PNA-DNA hybrid quadruplexes.....	130
Companies involved in PNA diagnostics.....	130
<b>Locked nucleic acids .....</b>	<b>131</b>
<b>Zip Nucleic Acids.....</b>	<b>131</b>
<b>Electrochemical detection of DNA .....</b>	<b>132</b>
Mediated nucleic acid oxidation.....	132
Detection of hybridized nucleic acid with cyclic voltametry .....	133
Electrochemical detection based on Toshiba's CMOS technology.....	133
Concluding remarks on electrochemical DNA detection .....	133
<b>Bead-based assay platforms .....</b>	<b>134</b>
<b>Scorpions™ technology.....</b>	<b>135</b>
The Scorpions reaction .....	135
Applications of Scorpions .....	135
<b>Nucleic acid lateral flow molecular diagnostics.....</b>	<b>136</b>
<b>Omics-based tests .....</b>	<b>137</b>

<b>3. Biochips, Biosensors, and Nanobiotechnology .....</b>	<b>139</b>
<b>Introduction to biochip technology.....</b>	<b>139</b>
<b>Applications of biochips in diagnostics .....</b>	<b>139</b>
GeneChip.....	140
<i>GeneChip Human Genome Arrays .....</i>	<i>141</i>
<i>AmpliChip CYP450.....</i>	<i>141</i>
Electronic detection of nucleic acids on microarrays.....	141
Microchip capillary electrophoresis .....	142
Strand displacement amplification on a biochip.....	142
Rolling circle amplification on microarrays .....	142
<i>LiquiChip-RCAT.....</i>	<i>142</i>
Fast PCR biochip .....	143
Multiplex microarray-enhanced PCR for DNA analysis .....	143
Multiplexed Molecular Profiling .....	143
Universal DNA microarray combining PCR and ligase detection reaction .....	144
Genomewide association scans .....	144
Whole genome chips/microarrays.....	145
Transposon insertion site profiling chip .....	145
Standardizing the microarrays .....	146
Companies involved in developing biochip technology for diagnostics .....	146
Future of biochip technology for molecular diagnostics.....	147
<b>Microfluidic chips .....</b>	<b>147</b>
Fish-on-chip .....	148

Lab-on-a-chip.....	148
LabCD .....	149
Micronics' microfluidic technology.....	149
Microfluidic chips/arrays using PCR .....	149
<i>Microfluidic automated DNA analysis using PCR</i> .....	149
<i>Digital PCR Array</i> .....	149
<i>Digital PCR on a SlipChip</i> .....	150
Microfluidic chips integrated with RCAT .....	150
Microfluidic chips integrated with PET .....	150
Companies developing microfluidic technologies .....	151
<b>Biosensor technologies .....</b>	<b>152</b>
Classification of biosensor technologies.....	153
DNA-based biosensors .....	154
<i>DNA hybridization biosensor chips</i> .....	154
<i>PCR-free DNA biosensor</i> .....	154
<i>DNA based biosensor to detects metallic ions</i> .....	155
Genetically engineered B lymphocytes.....	155
Biosensors immunoassays.....	155
PNA (peptide nucleic acid)-based biosensors .....	156
Protein-based biosensors .....	156
Antibody biosensors .....	156
Cell-based biosensors (cytosensors).....	156
<i>Multicell biosensors</i> .....	157
<i>Microbial biosensors</i> .....	157
Optical biosensors.....	158
<i>Surface plasmon resonance technology</i> .....	158
<i>Label-free optical biosensor</i> .....	159
Microsensors using with nano/microelectronic communications technology.....	159
Electrochemical sensors.....	159
<i>Enzyme electrodes for biosensing</i> .....	159
<i>Conductometric sensors</i> .....	160
<i>Electrochemical genosensors</i> .....	160
<i>Electrochemical nanobiosensor</i> .....	160
<i>Electrochemical microRNA biosensor</i> .....	161
Phototransistor biochip biosensor.....	162
Ribozyme-based sensors.....	162
<i>RiboReporters</i> .....	162
Concluding remarks and future prospects of biosensor technology .....	163
Companies developing biosensors for molecular diagnostics .....	164
<b>Molecular labels and detection.....</b>	<b>165</b>
Detection technologies for molecular labels .....	166
Fluorescence and chemiluminescence .....	166
<i>Fluorescence technologies for label detection</i> .....	166
<i>Companies with fluorescence and chemiluminescence products</i> .....	167
Molecular beacons.....	168
The Green fluorescent protein .....	169
Multiphoton detection radioimmunoassay .....	170
Multi-pixel photon counter .....	170
Enzyme labels and detection by fluorescence .....	170
Phase-sensitive flow cytometry.....	171
Microtransponder-based DNA diagnostics.....	171
Laboratory Multiple Analyte Profile .....	172
Multiple labels .....	172
<b>Protein-DNA chimeras for detection of small numbers of molecules.....</b>	<b>173</b>
<b>Single molecule detection .....</b>	<b>173</b>
Atomic force microscopy .....	174
Capillary electrophoresis .....	174
Confocal laser scanning .....	174
Time domain optical imaging technology.....	174
nCounter Analysis System.....	175
Spectrally resolved fluorescence lifetime imaging microscopy .....	175
<b>Molecular imaging .....</b>	<b>175</b>
Technologies for molecular imaging.....	175
<i>Positron emission tomography</i> .....	176
<i>Magnetic resonance imaging</i> .....	176
<i>Optoacoustic imaging</i> .....	176
<i>Computer tomography</i> .....	177
<i>Hyperpolarized diazirines for in vivo biomolecular imaging</i> .....	177
Basic research in molecular imaging .....	177
Devices for molecular imaging .....	177

Molecular imaging in clinical practice .....	178
Companies involved in molecular imaging .....	178
<b>Nanobiotechnology for molecular diagnostics.....</b>	<b>179</b>
Cantilever arrays .....	180
Diagnostics based on nanopore technology .....	181
DNA nanomachines for molecular diagnostics .....	181
Exosome-based molecular diagnostics .....	181
Fullerene photodetectors for chemiluminescence detection on microfluidic chip.....	182
Gold nanoparticles .....	182
Immunoliposome-PCR .....	182
Magnetic nanoparticles .....	183
Nanotechnology on a chip .....	184
NanoChip® Electronic Microarray.....	184
Nanobarcodes technology for molecular diagnostics .....	185
Nanosensors .....	185
<i>Detection of cocaine molecules by nanoparticle-labeled aptasensors.....</i>	<i>185</i>
<i>Nanosensors for glucose monitoring .....</i>	<i>186</i>
<i>PEBBLE nanosensors .....</i>	<i>186</i>
<i>Quartz nanobalance biosensor.....</i>	<i>186</i>
DNA nanoswitch-linked immunosorbent assay .....	186
Quantum dot technology.....	187
<i>Qdot nanobarcode for multiplexed gene expression profiling.....</i>	<i>188</i>
Resonance Light Scattering technology .....	188
Role of nanobiotechnology in improving molecular diagnostics.....	189
Companies involved in nanomolecular diagnostics.....	189
Concluding remarks about nanodiagnostics .....	192
Future of nanodiagnostics .....	193
<b>4. Proteomic Technologies for Molecular Diagnostics .....</b>	<b>195</b>
<b>Introduction .....</b>	<b>195</b>
<b>Proteomic technologies .....</b>	<b>195</b>
Biomarkers of disease .....	195
<i>Proteomic tools for biomarkers .....</i>	<i>195</i>
<i>Search for biomarkers in body fluids.....</i>	<i>196</i>
Captamers with proximity extension assay for proteins.....	196
Cyclical amplification of proteins .....	196
Detection of misfolded proteins by ELISA with exponential signal amplification .....	197
Detection of proteins by Western blot.....	197
Diagnostics based on designed repeat proteins .....	197
Differential Peptide Display .....	198
Light-switching excimer probes.....	198
MALDI-TOF MS .....	199
Molecular beacon aptamer .....	199
Molecular beacon assay .....	200
Proteomic patterns.....	200
Real-time PCR for protein quantification.....	201
<b>Protein biochip technologies.....</b>	<b>201</b>
ProteinChip .....	202
LabChip for protein analysis .....	203
TRINECTIN proteome chip.....	203
Protein chips for antigen-antibody interactions molecular diagnostics .....	203
Microfluidic devices for proteomics-based diagnostics .....	204
Nanotechnology-based protein biochips/microarrays .....	204
<i>Nanoparticle protein chip .....</i>	<i>204</i>
<i>Protein nanobiochip.....</i>	<i>204</i>
<i>Protein biochips based on fluorescence planar wave guide technology .....</i>	<i>205</i>
New developments in protein chips/microarrays .....	206
<i>Antibody microarrays .....</i>	<i>206</i>
<i>Aptamer-based protein biochip .....</i>	<i>206</i>
<i>Multiplexed Protein Profiling on Microarrays.....</i>	<i>206</i>
<i>Proteomic pattern analysis.....</i>	<i>207</i>
<i>Single molecule array.....</i>	<i>207</i>
<i>Viral protein chip .....</i>	<i>207</i>
Commercial development of protein chips for molecular diagnostics .....	208
Proteome Identification Kit.....	209
<b>Laser capture microdissection (LCM).....</b>	<b>210</b>
LCM technology .....	210
Applications of LCM in molecular diagnostics .....	210
<b>Proteomic diagnosis of CNS disorders.....</b>	<b>210</b>
Cerebrospinal fluids tests based on proteomics .....	211



Urine tests for CNS disorders based on proteins in urine .....	211
Diagnosis of CNS disorders by examination of proteins in the blood.....	212
Diagnosis of CNS disorders by examination of proteins in tears.....	213
Role of proteomics in the diagnosis of Alzheimer's disease .....	213
Role of proteomics in the diagnosis of Creutzfeldt-Jakob disease.....	213
Future prospects of use of proteomics for diagnosis of CNS disorders .....	214
<b>Concluding remarks on the use of proteomics in diagnostics.....</b>	<b>214</b>

<b>5. Molecular Diagnosis of Genetic Disorders .....</b>	<b>215</b>
<b>Introduction .....</b>	<b>215</b>
<b>Cytogenetics .....</b>	<b>216</b>
FISH with probes to the telomeres .....	216
Single copy FISH probes .....	216
Comparative genomic hybridization .....	217
<b>Use of biochips in genetic disorders.....</b>	<b>217</b>
Representational oligonucleotide microarray analysis.....	218
<b>Diagnosis of genomic rearrangements by multiplex PCR .....</b>	<b>218</b>
<b>Quantitative fluorescent PCR .....</b>	<b>218</b>
<b>Mutation detection technologies .....</b>	<b>219</b>
PCR-based methods for mutation detection .....	220
<i>Cleavase Fragment Length Polymorphism .....</i>	<i>220</i>
<i>Direct dideoxy DNA sequencing .....</i>	<i>220</i>
<i>Digital Genetic Analysis (DGA).....</i>	<i>220</i>
<i>Fluorescence-based directed termination PCR.....</i>	<i>221</i>
<i>Fluorescence melting curve analysis for multiplex mutation detection .....</i>	<i>221</i>
<i>Heteroduplex analysis .....</i>	<i>222</i>
<i>Restriction fragment length polymorphism .....</i>	<i>222</i>
<i>Single-stranded conformation polymorphism (SSCP) analysis .....</i>	<i>222</i>
<i>TaqMan real-time PCR .....</i>	<i>223</i>
Non-PCR methods for mutation detection.....	223
<i>Arrayed primer extension.....</i>	<i>223</i>
<i>BEAMing (beads, emulsion, amplification, and magnetics).....</i>	<i>224</i>
<i>ELISA-protein truncation test .....</i>	<i>224</i>
<i>Enzymatic mutation detection.....</i>	<i>224</i>
<i>Specific anchor nucleotide incorporation .....</i>	<i>225</i>
<i>Conversion analysis for mutation detection .....</i>	<i>225</i>
Biochip technologies for mutation detection.....	225
<i>Combination of FISH and gene chips .....</i>	<i>226</i>
<i>Haplotype Specific Extraction .....</i>	<i>226</i>
Use of biosensors for detection of mutations .....	227
<b>Technologies for SNP analysis .....</b>	<b>227</b>
Acoustic detection of DNA conformation in genetic assays combined with PCR .....	228
DNA sequencing .....	228
Electrochemical DNA probes.....	229
<i>Use of NanoChip for detection of SNPs.....</i>	<i>229</i>
Single base extension-tag array.....	229
Laboratory Multiple Analyte Profile .....	229
SNP genotyping with gold nanoparticle probes.....	230
PCR-CTPP (confronting two-pair primers).....	230
PCR using one primer amplification of PCR-CTPP products.....	230
Peptide nucleic acid probes for SNP detection .....	231
SNP genotyping on a genome-wide amplified DOP-PCR template .....	231
Pyrosequencing .....	231
Reversed enzyme activity DNA interrogation test .....	232
Smart amplification process version 2 .....	233
Zinc finger proteins .....	233
UCAN method (Takara Biomedical).....	233
<b>Biochip and microarray-based detection of SNPs.....</b>	<b>233</b>
SNP genotyping by MassARRAY .....	233
Electronic dot blot assay .....	234
Biochip combining BeadArray and ZipCode technologies .....	234
SNP-IT primer-extension technology .....	235
OmniScan SNP genotyping.....	235
Affymetrix SNP genotyping array .....	235
Concluding remarks on SNP genotyping.....	235
Limitations of SNP in genetic testing.....	236
Haplotyping versus SNP genotyping .....	236
Nanofluidics technology for high throughput SNP genotyping.....	237
Companies involved in developing technologies/products for SNP analysis .....	237
<b>Role of copy number variations in genetic diagnostic testing .....</b>	<b>238</b>

CNVs in various diseases .....	239
<i>CNVs in genetic epilepsy syndromes</i> .....	239
<i>CNVs associated with schizophrenia</i> .....	239
Methods for determination of CNVs .....	239
<i>Digital array for CNV detection</i> .....	240
<i>Wellcome Trust Case Control Consortium CNV typing array</i> .....	240
<i>CNVer algorithm for CNV detection</i> .....	240
<i>CNVnator for discovery of CNVs and genotyping</i> .....	241
Study of rare variants in pinpointing disease-causing genes .....	241
<b>Chromothripsis and congenital abnormalities .....</b>	<b>242</b>
<b>Role of whole genome sequencing in screening of newborns .....</b>	<b>242</b>
<b>Prenatal DNA diagnosis .....</b>	<b>242</b>
Invasive prenatal diagnostic procedures .....	243
<i>Amniocentesis</i> .....	243
<i>Chorionic villus sampling</i> .....	243
Molecular methods for prenatal diagnosis .....	243
<i>aCGH for prenatal diagnosis</i> .....	243
<i>BAC HD Scan test</i> .....	244
<i>FISH for prenatal diagnosis</i> .....	244
<i>PCR for prenatal diagnosis</i> .....	244
<i>In vivo gene expression analysis of the living human fetus</i> .....	245
Non-invasive prenatal molecular diagnostic procedures .....	245
<i>Fetal cells separation from maternal blood for genetic diagnosis</i> .....	245
<i>Digital relative mutation dosage in maternal plasma</i> .....	245
<i>Prenatal testing based on transrenal DNA from urine</i> .....	246
Tests on fetal DNA in maternal blood .....	246
<i>Sequencing-based methods for prenatal diagnosis from maternal DNA</i> .....	246
<i>cfDNA testing vs routine screening in first trimester of pregnancy</i> .....	248
<i>Noninvasive WGS of the fetus</i> .....	249
<i>Directed DNA analysis of maternal blood</i> .....	249
Applications of prenatal diagnosis .....	250
<i>Antenatal screening for Down's syndrome</i> .....	251
<i>Diagnosis of congenital infections</i> .....	252
<i>Diagnosis of eclampsia</i> .....	252
<i>Identification of cancers in pregnant women during NIPT</i> .....	252
<b>Preimplantation genetic diagnosis .....</b>	<b>252</b>
Technologies for preimplantation genetic diagnosis .....	253
<i>PCR for preimplantation genetic diagnosis</i> .....	253
<i>FISH for preimplantation genetic diagnosis</i> .....	253
<i>Microarrays for preimplantation genetic diagnosis</i> .....	254
<i>Whole genome sequencing for PGD</i> .....	254
Conditions detected by preimplantation genetic diagnosis .....	254
The future of preimplantation genetic diagnosis .....	255
<b>Companies involved in prenatal/preimplantation diagnosis .....</b>	<b>256</b>
<b>Cystic fibrosis .....</b>	<b>257</b>
Detection of CFTR gene mutations .....	257
CFTR technologies of various companies .....	258
<i>Asuragen's bead array test</i> .....	259
<i>Ambry CF Test</i> .....	259
<i>Biochip for CF diagnosis</i> .....	260
<i>CF Plus™ Tag-It Cystic Fibrosis Kit</i> .....	260
<i>Genzyme's CF gene sequencing</i> .....	260
<i>HerediT™ (SEQUENOM) CF carrier screening test</i> .....	260
<i>Identification of CF variants by PCR/Oligonucleotide Ligation Assay</i> .....	261
<i>MiSeqDx sequencing-based CF assays</i> .....	261
<i>Serum proteomic signature for CF using antibody microarrays</i> .....	261
Guidelines for genetic screening for CF .....	261
<b>Congenital adrenal hyperplasia .....</b>	<b>262</b>
<b>Primary immunodeficiencies .....</b>	<b>262</b>
<b>Hematological disorders .....</b>	<b>263</b>
Hemoglobinopathies .....	263
<i>Sickle cell anemia</i> .....	263
<i>Thalassemia</i> .....	264
<i>Paroxysmal nocturnal hemoglobinuria</i> .....	264
Hemophilia .....	265
Hereditary hemochromatosis .....	265
<b>Polycystic kidney disease .....</b>	<b>265</b>
<b>Hereditary metabolic disorders .....</b>	<b>266</b>
Lesch-Nyhan Syndrome .....	266
Gaucher's Disease .....	266

Acute Intermittent Porphyria .....	267
Phenylketonuria .....	267
Hereditary periodic fever .....	267
<b>Achondroplasia .....</b>	<b>268</b>
<b>Molecular diagnosis of eye diseases .....</b>	<b>268</b>
Molecular diagnosis of retinitis pigmentosa .....	268
Genetic screening for glaucoma .....	269
<b>Role of molecular diagnostics in rheumatoid arthritis .....</b>	<b>269</b>
<b>Molecular diagnosis of neurogenetic disorders .....</b>	<b>269</b>
Alzheimer's disease .....	271
Autism spectrum disorders .....	271
<i>CNVs associated with autism .....</i>	<i>272</i>
Charcot-Marie Tooth disease .....	272
Down syndrome .....	273
Duchenne and Becker muscular dystrophy .....	273
eNOS gene polymorphisms as predictor of cerebral aneurysm rupture .....	274
Fragile X syndrome .....	275
Huntington disease .....	275
Hereditary neuropathy with liability to pressure palsies .....	276
Mitochondrial disorders affecting the nervous system .....	276
Parkinson's disease .....	276
Pompe's disease .....	277
Spinal muscular atrophy .....	278
Triple repeat disorders .....	278
<b>Genetic testing for disease predisposition .....</b>	<b>279</b>
Direct-to-consumer genetic tests .....	279
<b>6. Molecular diagnosis of cardiovascular disorders .....</b>	<b>281</b>
<b>Introduction .....</b>	<b>281</b>
<b>Coronary heart disease .....</b>	<b>282</b>
Genomics of coronary heart disease .....	282
Diagnosis of coronary artery disease based on gene expression .....	283
<b>Cardiomyopathy .....</b>	<b>283</b>
Hypertrophic cardiomyopathy .....	283
Idiopathic dilated cardiomyopathy .....	284
<b>Cardiac arrhythmias .....</b>	<b>284</b>
Genetic tests for cardiac arrhythmias .....	284
Long Q-T syndrome .....	284
Familial atrial fibrillation .....	285
Idiopathic ventricular fibrillation .....	285
<b>Congestive heart failure .....</b>	<b>285</b>
<b>Hypertension .....</b>	<b>286</b>
<b>Disturbances of blood lipids .....</b>	<b>286</b>
Familial dyslipoproteinemias .....	286
Hypercholesterolemia .....	286
<b>Thrombotic disorders .....</b>	<b>287</b>
Factor V Leiden mutation .....	287
Pulmonary embolism .....	288
Hereditary thrombophilia .....	288
<b>Molecular diagnostics for monitoring heart transplant rejection .....</b>	<b>288</b>
AlloMap® molecular expression testing .....	288
<b>Commercial molecular diagnostics for cardiovascular disorders .....</b>	<b>289</b>
<b>7. Molecular Diagnosis of Infections .....</b>	<b>291</b>
<b>Introduction .....</b>	<b>291</b>
<b>Molecular techniques for the diagnosis of infections .....</b>	<b>291</b>
Antibody-enhanced microplate hybridization assays .....	292
Bacteriophage-based methods for detection of bacteria .....	292
Biochips/microarrays for detection of microorganisms .....	293
<i>Lawrence Livermore Microbial Detection Array .....</i>	<i>293</i>
Biosensors for detection of microorganisms .....	293
<i>Ibis T5000™ Biosensor System .....</i>	<i>293</i>
<i>Molecular Mirroring Technology .....</i>	<i>293</i>
DNA enzyme immunoassay .....	294
DNA biochip/microarray in diagnosis of infections .....	294
DNA-based typing methods .....	295
<i>Restriction fragment length polymorphism analysis .....</i>	<i>295</i>
<i>Ribotyping .....</i>	<i>295</i>
<i>Random amplified polymorphic DNA .....</i>	<i>295</i>
<i>Combinatorial DNA melting assay .....</i>	<i>295</i>

Electrochemical detection of pathogens .....	296
Field Activated Sample Treatment (FAST) .....	296
FISH for detection of infections.....	296
<i>hemoFISH assay</i> .....	297
Helicase-dependent isothermal amplification for rapid detection of pathogens .....	297
High resolution melt analysis for diagnosis of infections .....	297
Immunomagnetic cell capture.....	297
Ligase chain reaction.....	298
Multiplex PCR for detection of infections.....	298
PCR electrospray ionization mass spectrometry .....	298
Metagenomic pyrosequencing.....	299
<i>Dual priming oligonucleotide for multiplex PCR</i> .....	300
<i>Multiplex amplified nominal tandem repeat analysis</i> .....	301
Tests for sepsis.....	301
<i>LightCycler® SeptiFast Test</i> .....	301
<i>NanoDx™</i> .....	302
<i>SeptiCyte Triage assay</i> .....	302
<i>SepsiTest™</i> .....	302
<i>VYOO® Sepsis Test</i> .....	302
Nanopore-based diagnosis of infections .....	303
NASBA for detection of microorganisms .....	303
Nucleic acid probes .....	303
Neutrophil CD11b expression as a diagnostic marker.....	304
Optical Mapping.....	304
PNA-FISH for diagnosis of infections.....	304
Proteomic technologies for diagnosis of infections .....	305
<i>Mass spectrometry for microbial identification</i> .....	305
QuantIFERON® technology for pre-molecular diagnosis of infections .....	305
Quantitative reverse-transcription PCR for bacterial diagnostics .....	306
Rapid electrochemical diagnosis of infections.....	306
Rupture event scanning .....	307
Real-time single-molecule imaging of virus particles.....	307
Single-strand conformational polymorphism .....	307
SmartGene platform for identifying pathogens based on genetic sequences .....	307
Tessera array technology.....	307
Unyvero Solution .....	308
<b>Applications, advantages and limitations of molecular diagnostics.....</b>	<b>308</b>
Molecular diagnostics versus other microbial detection technologies .....	308
Advantages of nucleic acid-based diagnostics in infections .....	308
Drawbacks of nucleic acid-based diagnostics in infections .....	309
Nanotechnology for detection of infectious agents.....	309
<b>Bacterial infections .....</b>	<b>310</b>
Mycobacterium tuberculosis .....	313
<i>Conventional diagnosis of tuberculosis</i> .....	314
<i>Combined tuberculin testing and ELISpot<sup>PLUS</sup> assay</i> .....	314
<i>Microscopic Observation Drug Susceptible Assay for tuberculosis</i> .....	315
<i>Molecular diagnostics for tuberculosis</i> .....	315
<i>Blood-based gene expression test for detecting TB</i> .....	317
<i>Diagnosis of TB in a POC setting</i> .....	317
<i>Diagnosis of drug-resistant MTB infection</i> .....	317
<i>GeneXpert MTB/RIF (eXpert) automated molecular test for MTB</i> .....	318
<i>QuantIFERON-TB Gold test</i> .....	319
Diagnosis of other mycobacteria .....	319
<i>Leprosy and M. leprae</i> .....	319
Bacteria associated with bacterial vaginosis.....	320
Chlamydial infections.....	320
Neisseria gonorrhoeae .....	321
Trichomonas vaginalis .....	322
Streptococcal infections .....	322
<i>Group B Streptococci</i> .....	322
<i>Group A Streptococcus and Streptococcus dysgalactiae</i> .....	323
Pseudomonas aeruginosa.....	323
Helicobacter pylori .....	323
Vibrio Cholerae.....	324
Lyme disease .....	324
Mycoplasmas.....	325
<b>Fungal infections .....</b>	<b>326</b>
PCR-based tests for fungal infections.....	326
DNA barcode marker for fungi .....	327
DNA sequencing for fungal infections.....	327

MALDI-TOF MS for diagnosis of fungal infections .....	327
Aspergillus .....	328
Candida species .....	328
<b>Viral infections.....</b>	<b>329</b>
Simultaneous testing of multiple viruses by VirScan .....	329
Carbon nanotubes-based detection of viruses .....	329
FDA-approved molecular diagnostics for viral infections .....	330
HIV/AIDS.....	331
<i>Diagnosis of HIV</i> .....	331
<i>Detection of HIV provirus</i> .....	332
<i>Global Surveillance of HIV-1 genetic variations</i> .....	332
<i>Genotyping for drug-resistance in HIV</i> .....	332
<i>Neonatal screening of infants of HIV-positive mothers</i> .....	334
<i>Phenotyping as predictor of drug susceptibility/resistance in HIV</i> .....	334
<i>POC testing for HIV</i> .....	335
<i>PCR for resolution of indeterminate Western blot</i> .....	335
<i>Screening of cadaveric tissue donors</i> .....	335
<i>Tests used for quantification of HIV</i> .....	335
<i>Conclusions about HIV diagnostics</i> .....	336
Hepatitis viruses .....	337
<i>Hepatitis A virus</i> .....	337
<i>Hepatitis B virus</i> .....	338
<i>Hepatitis C virus</i> .....	338
<i>Detection and quantification of HCV RNA</i> .....	339
<i>Quantification of HCV RNA levels as a guide to antiviral therapy</i> .....	340
<i>Electrochemical DNA chip for diagnosis of HCV</i> .....	340
<i>HCV Genotyping as a guide to therapy</i> .....	340
<i>Hepatitis E</i> .....	340
Enteroviruses .....	341
Adenoviruses.....	342
Rhinoviruses .....	342
Herpes viruses.....	342
<i>Herpes simplex virus</i> .....	342
<i>Genital and neonatal herpes simplex</i> .....	343
<i>Human cytomegalovirus infections</i> .....	344
<i>Epstein-Barr virus</i> .....	344
Human papilloma virus .....	345
<i>Molecular diagnostics for HPV</i> .....	345
Detection of encephalitis viruses .....	346
<i>West Nile and St. Louis encephalitis</i> .....	346
<i>Venezuelan equine encephalitis virus</i> .....	347
Detection of noroviruses .....	347
Detection of dengue virus .....	347
Detection of Ebola virus .....	347
Detection of Zika virus.....	348
<b>Protozoal infections.....</b>	<b>349</b>
Amebiasis .....	349
Cryptosporidium parvum.....	349
Leishmaniasis .....	350
Malaria .....	350
Neurocysticercosis .....	350
Pneumocystis carinii.....	351
Toxoplasmosis.....	351
<b>Infections of various systems.....</b>	<b>352</b>
CNS infections .....	352
<i>Molecular diagnosis in bacterial meningitis</i> .....	352
<i>Molecular diagnosis in herpes simplex encephalitis</i> .....	352
<i>Diagnosis of transmissible spongiform encephalopathies</i> .....	353
Molecular diagnosis of respiratory viruses .....	354
<i>Avian influenza H7N9</i> .....	354
<i>H1N1 influenza</i> .....	355
<i>Influenza viruses</i> .....	358
<i>Avian influenza H5N1</i> .....	360
<i>Respiratory syndromes associated with coronavirus</i> .....	363
Gastrointestinal infections .....	364
Periodontal infections .....	365
Diagnosis of urinary infections by a biosensor.....	366
Role of molecular diagnosis in sexually transmitted infections.....	367
Role of molecular diagnostics in septicemia .....	367
<b>Limitations and needs of diagnostics for infections .....</b>	<b>367</b>

Differentiation between live and antibiotic-killed bacteria .....	368
Cell-based methods for identifying pathogenic microorganisms .....	369
<i>Cell-based virus assays</i> .....	369
<i>Cell-based detection of host response to infection</i> .....	369
<b>Role of molecular diagnostics in hospital acquired infections .....</b>	<b>369</b>
Molecular diagnostics for detection of drug resistance in infections .....	370
Detection of hospital-acquired bacterial infections .....	370
<i>Detection of methicillin-resistant S. aureus</i> .....	370
<i>Whole-genome sequencing for investigation of MRSA outbreaks</i> .....	372
<i>Detection of carbapenemase-producing Gram-negative bacteria</i> .....	372
<i>Detection of vancomycin-resistant enterococci</i> .....	372
<i>Detection of hospital-acquired C. difficile</i> .....	373
<i>Integrated device for rapid detection of organisms associated HAI</i> .....	375
<i>Bacterial genome sequencing in antimicrobial resistance</i> .....	375
Detection of hospital-acquired viral infections .....	375
<i>Molecular diagnosis of BK virus</i> .....	375
<i>Diagnosis of hospital-acquired rotavirus gastroenteritis</i> .....	376
<b>Molecular diagnostics and the microbiome .....</b>	<b>376</b>
Human Microbiome Project.....	376
Application of metagenomics for study of the microbiome .....	377
MicroBiome Analysis Center .....	377
<b>Concluding remarks and future of diagnosis of infections.....</b>	<b>377</b>
Rapid point-of-care diagnosis of infections .....	378
Diagnosis of viruses using protein fingerprinting .....	381
QIAplex PCR multiplex technology.....	381
Role of PCR vs sequencing for diagnosis of infections.....	382
<b>Companies involved in molecular diagnosis of infectious diseases .....</b>	<b>382</b>

## **8. Molecular Diagnosis of Cancer .....** **385**

<b>Introduction .....</b>	<b>385</b>
<b>Cancer genomics.....</b>	<b>385</b>
Cancer genes .....	386
Oncogenes .....	386
Tumor Suppressor Genes .....	386
<i>BRCA mutations</i> .....	388
<i>p53</i> .....	388
<i>p16</i> .....	388
CNVs in cancer .....	388
<i>Allele-specific copy number analysis of tumors</i> .....	389
Viruses and cancer .....	389
<i>Detecting viral agents in cancer</i> .....	390
<b>Conventional cancer diagnosis.....</b>	<b>391</b>
<b>Molecular techniques for cancer diagnosis.....</b>	<b>392</b>
Exosome-based molecular diagnosis of cancer .....	393
Expression profiling of tumor cells sorted by flow cytometry .....	394
MicroRNA expression profiling for cancer diagnostics .....	394
Genome analysis at the molecular level .....	394
Mutation detection by sequencing .....	395
Quality control of NGS in oncology .....	395
Biomarkers in cancer .....	395
<i>Circulating nucleic acids as potential biomarkers of cancer</i> .....	396
<i>Circulating nucleosomes in serum of cancer patients</i> .....	396
<i>Detection of DNA methylation</i> .....	397
<i>eTag assay system for cancer biomarkers</i> .....	399
<i>HAAH as a biomarker for cancer</i> .....	399
<i>LigAmp for detection of gene mutations in cancer</i> .....	399
<i>Mitochondrial DNA as a cancer biomarker</i> .....	400
<i>Oncoproteins as biomarkers for cancer</i> .....	400
<i>Sequencing-based approaches for detection of cancer biomarkers</i> .....	401
Molecular fingerprinting of cancer .....	401
Fluorescent in situ hybridization.....	402
Genetic analysis of cancer.....	402
<i>Comparative genomic hybridization in cancer diagnostics</i> .....	402
<i>Loss of heterozygosity</i> .....	403
<i>Digital karyotyping</i> .....	403
<i>Gene expression profiles predict chromosomal instability in tumors</i> .....	404
PCR Techniques .....	404
<i>Cold-PCR</i> .....	404
<i>Real-time qPCR for diagnosis of cancer</i> .....	405
<i>Real-time PCR with myT™ Primer reagents</i> .....	405

Antibody-based diagnosis of cancer.....	405
<i>Monoclonal antibodies for diagnosis of cancer</i> .....	405
<i>Recombinant antibodies as a novel approach to cancer diagnosis</i> .....	406
Combined immunological and nucleic acid tests .....	406
<i>Combination of MAbs and RT-PCR</i> .....	406
<i>Immunobead RT-PCR</i> .....	406
Assays for determining susceptibility to cancer .....	407
Gene expression profiling in cancer .....	407
<i>Microarrays for gene expression profiling in cancer</i> .....	407
<i>Serial analysis of gene expression (SAGE)</i> .....	408
<i>Suppression subtractive hybridization</i> .....	408
<i>Cancer tests based on gene expression profiling</i> .....	408
Measurement of telomerase activity .....	409
Liquid biopsy for detection of circulating tumor cells in blood.....	410
<i>ApoStream for POC detection of CTCs</i> .....	410
<i>BEAMing technology for quantification of circulating tumor DNA</i> .....	410
<i>CEE (cell enrichment and extraction) technology</i> .....	411
<i>CellSearch</i> .....	411
<i>CellTracks® AutoPrep® System</i> .....	411
<i>CTScope system for detection of CTCs</i> .....	412
<i>CTChip™</i> .....	412
<i>CTC sorting by acoustic waves</i> .....	412
<i>Detection of circulating tumor DNA</i> .....	412
<i>Droplet digital PCR for examination of cell free plasma DNA in cancer</i> .....	413
<i>DNA nanospheres for isolation of CTCs</i> .....	413
<i>Fiber-optic array scanning technology</i> .....	413
<i>Herringbone-chip for detection of CTCs</i> .....	414
<i>IsoFlux System</i> .....	414
<i>Lab-on-chip for the isolation and detection of CTCs</i> .....	414
<i>MagSweeper</i> .....	415
<i>Nano-Velcro to capture CTCs for diagnosis of cancer</i> .....	415
<i>NanoFlares for detection of CTCs</i> .....	415
<i>Companies developing tests for detection of CTCs</i> .....	415
<i>Future of detection of cancer cells in blood</i> .....	416
Epithelial aggregate separation and isolation .....	416
Proteomic technologies for the molecular diagnosis of cancer .....	417
<i>Proteomic technologies for tumor biomarkers</i> .....	417
<i>Affibodies as contrast agents for imaging in cancer</i> .....	417
<i>Aptamer-based technology for protein signatures of cancer cells</i> .....	418
<i>Aptamer probes for in vivo diagnosis of cancer</i> .....	418
<i>Aptamers for combined diagnosis and therapeutics of cancer</i> .....	419
<i>Automated image analysis of nuclear protein distribution</i> .....	419
<i>Laser capture microdissection in oncology</i> .....	419
<i>Layered expression scanning</i> .....	420
<i>Membrane-type serine protease-1</i> .....	420
<i>Survivin and molecular diagnosis of cancer</i> .....	421
Biochip/microarrays for cancer diagnosis .....	421
<i>Role of DNA microarrays in gene expression profiling</i> .....	422
<i>Biochip detection of FHIT gene</i> .....	422
Multiplexed single-cell analysis of FFPE cancer tissue samples .....	422
Nanobiotechnology for early detection of cancer .....	423
<i>Detection of nanoparticle self assembly in tumors by MRI</i> .....	423
<i>Differentiation between normal and cancer cells by nanosensors</i> .....	423
<i>Magnetic nanoparticle probes</i> .....	423
<i>Quantum dots for early detection of cancer</i> .....	424
Molecular imaging of cancer .....	425
<i>In vivo imaging of single cancer cells</i> .....	425
<i>In vivo molecular imaging of cancer</i> .....	425
<i>In vivo tumor illumination by adenoviral-GFP</i> .....	426
<i>PET for in vivo molecular diagnosis of cancer</i> .....	426
<i>Radiolabeled peptide-based targeting probes for cancer imaging</i> .....	427
<i>Xenon-enhanced MRI</i> .....	427
Detection of micrometastases.....	427
Detection of cancer stem cells .....	428
Detection of origin in cancers of unknown primary .....	428
<b>Molecular diagnosis of cancers of various organs .....</b>	<b>429</b>
Brain tumors .....	429
<i>Molecular diagnostic methods for brain tumors</i> .....	429
<i>Glioblastoma multiforme</i> .....	429
<i>Circulating microvesicles as biomarkers of glioblastoma</i> .....	430

<i>Circulating tumor cells in glioblastoma</i> .....	430
<i>Combination of neuroimaging and DNA microarray analysis in GBM</i> .....	431
<i>Medulloblastoma</i> .....	431
<i>Multigene predictor of outcome in GBM</i> .....	431
<i>Oligodendroglioma</i> .....	431
<i>Advantages and limitations of molecular diagnosis of brain tumors</i> .....	432
Breast cancer .....	432
<i>Breast cancer genes</i> .....	433
<i>Circulating tumor cells and nucleic acid biomarkers of breast cancer</i> .....	434
<i>Genomic profiles of breast cancer</i> .....	434
<i>Imaging biopsy specimens as alternative to histological examination</i> .....	435
<i>Microchimerism and breast cancer</i> .....	435
<i>Molecular diagnostic tests for breast cancer</i> .....	435
<i>Molecular diagnostics for management of breast cancer</i> .....	439
<i>Mouse ESC-based assays to evaluate mutations in BRCA2</i> .....	444
<i>One step nucleic acid amplification assay for breast sentinel nodes</i> .....	444
<i>Prognostic testing for of breast cancer</i> .....	444
<i>Prediction of recurrence in breast cancer for personalizing therapy</i> .....	446
Cervical cancer .....	448
Colorectal cancer .....	449
<i>ColoVantage CRC test</i> .....	449
<i>Detection of familial adenomatous polyposis coli</i> .....	449
<i>Detection of CRC at precancerous state</i> .....	449
<i>Detection of circulating tumor cells in CRC</i> .....	450
<i>Diagnosis of hereditary nonpolyposis CRC</i> .....	450
<i>Diagnosis of CRC from DNA in stools</i> .....	451
<i>Droplet Digital™ PCR for detection of KRAS Mutations</i> .....	451
<i>Early diagnosis of CRC from blood samples</i> .....	451
<i>Guanylyl cyclase C-based tests for CRC</i> .....	452
<i>Minimally invasive screening for CRC</i> .....	452
<i>Multitarget stool DNA testing for CRC screening</i> .....	453
Gastric cancer .....	453
Head and neck cancer .....	453
<i>Nanobiochip sensor technique for analysis of oral cancer biomarkers</i> .....	453
<i>ProteinChip for diagnosis of head and neck cancer</i> .....	454
Hematological malignancies .....	454
<i>Chromosome translocations</i> .....	454
<i>Flow cytometry in diagnosis of leukemia</i> .....	455
<i>Gene chip technology</i> .....	455
<i>Hairy-cell leukemia</i> .....	455
<i>Laboratory assessment of leukemia</i> .....	455
<i>Molecular probes</i> .....	456
<i>Minimal residual disease</i> .....	457
<i>Molecular diagnosis in myelodysplastic syndromes</i> .....	457
<i>Screening of gene mutations in chronic myeloproliferative diseases</i> .....	458
Lung cancer .....	458
<i>Molecular subtyping of lung cancer</i> .....	460
Melanoma .....	461
Ovarian cancer .....	461
<i>Mutation of genes</i> .....	462
<i>Relevance of genetic testing to management of ovarian cancer</i> .....	462
<i>Serum biomarkers for early detection of ovarian cancer</i> .....	462
<i>Biomarkers of ovarian cancer</i> .....	462
<i>Concluding remarks on testing for ovarian cancer</i> .....	463
Pancreatic cancer.....	464
<i>Proteomic techniques for diagnosis of pancreatic cancer</i> .....	464
<i>Detection of KRAS mutations in pancreatic cancer</i> .....	464
Prostate cancer.....	464
<i>Identification of genetic risks for prostate cancer</i> .....	465
<i>Gene expression analysis of prostate cancer</i> .....	465
<i>Huntingtin Interacting Protein 1</i> .....	465
<i>Integrative genomic and proteomic profiling of prostate cancer</i> .....	465
<i>LCM for diagnosis of prostate cancer</i> .....	466
<i>Liquid biopsy for prostate cancer patients</i> .....	466
<i>Nanotechnology for early detection of recurrence of prostate cancer</i> .....	467
<i>PCA3 gene detection in urine</i> .....	467
<i>PCR assay for assessing silencing of protein cadherin 13 gene</i> .....	468
<i>Prolaris test</i> .....	468
<i>Prostate biopsy for detection of prostatic intraepithelial neoplasia</i> .....	468
<i>Prostate Core Mitomic Test™</i> .....	468



<i>Prostat Health Index</i> .....	469
<i>Screening of multiple SNPs for risk of prostate cancer</i> .....	469
<i>Semen testing for prostate cancer biomarkers</i> .....	469
<i>Serum-protein fingerprinting in prostate cancer</i> .....	470
Thyroid cancer.....	470
<i>Afirma gene expression classifier for inconclusive thyroid biopsies</i> .....	470
<i>Gene expression biomarkers of thyroid cancer</i> .....	470
<i>Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer</i> .....	471
<i>miRNA expression profiling in thyroid cancer</i> .....	471
Urinary bladder cancer .....	472
<b>Role of molecular diagnostics in the management of cancer .....</b>	<b>472</b>
Risk assessment and prevention of cancer .....	472
Role of molecular diagnosis in the design of future cancer therapies .....	473
Molecular classification of cancer.....	473
Determination of cancer prognosis .....	474
<i>Prognosis by tumor classification</i> .....	474
<i>Prognosis by cancer gene expression</i> .....	474
Selection of anticancer drugs based on molecular diagnosis .....	474
Integrated genome-wide analysis of cancer for diagnosis and therapy .....	475
<b>Personalized therapy for cancer patients.....</b>	<b>475</b>
Pharmacogenetics and cancer therapy .....	476
Molecular diagnostics as an aid to selection of cancer therapy .....	476
Drug resistance in cancer.....	477
<b>Role of organizations in molecular diagnosis of cancer.....</b>	<b>477</b>
Role of NCI in molecular diagnosis of cancer.....	477
<i>Molecular profiling of cancer</i> .....	477
<i>Cancer Genome Atlas</i> .....	478
<i>Cancer Genetic Markers of Susceptibility Project</i> .....	479
<i>Support for future research in molecular diagnosis of cancer</i> .....	479
Role of the International Cancer Genome Consortium .....	479
<b>Future prospects of molecular diagnosis of cancer .....</b>	<b>480</b>
<b>Companies involved in molecular diagnosis of cancer.....</b>	<b>480</b>

## **9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare ... 485**

<b>Introduction .....</b>	<b>485</b>
<b>Molecular diagnostics in biopharmaceutical industry.....</b>	<b>485</b>
Molecular diagnostic technologies and drug discovery .....	486
Molecular diagnostics and pharmacogenetics .....	486
Molecular toxicology .....	487
<i>Gene expression studies for toxicology</i> .....	488
<i>Toxicogenomics</i> .....	488
<i>Toxicoproteomics</i> .....	489
Mitochondrial assays .....	490
MetaChip/Datachip.....	490
Molecular diagnostics and pharmacogenomics .....	491
Molecular diagnostics and therapeutic drug monitoring .....	492
Applications molecular diagnostics in gene therapy .....	492
<i>Use of PCR to study biodistribution of gene therapy vectors</i> .....	492
<i>PCR for verification of the transcription of DNA</i> .....	493
<i>In situ PCR for direct quantification of gene transfer into cells</i> .....	493
<i>Detection of retroviruses by reverse transcriptase (RT)-PCR</i> .....	493
<i>Assessment of safety issues of gene transfer</i> .....	493
<i>Quantitative PCR for monitoring the effectiveness of gene therapy</i> .....	494
<i>Use of FISH for analysis of adeno-associated viral vector integration</i> .....	494
<i>Monitoring of gene expression by green fluorescent protein</i> .....	494
Quality control of protein therapeutics and vaccines .....	494
Detection of microbial contamination in biopharmaceutical manufacturing.....	495
<i>Role of PCR in detecting contamination</i> .....	495
<i>Systems for rapid detection of contaminants</i> .....	495
<i>Contamination of biopharmaceuticals with prions</i> .....	496
DNA tagging for control and tracing of drug distribution channels .....	496
<b>Molecular diagnostics for organ transplantation .....</b>	<b>497</b>
HLA typing .....	497
Sequencing for HLA typing .....	498
Commercial products for transplant molecular diagnostics.....	498
Post-cardiac transplant patient monitoring for rejection .....	500
<b>Application of molecular diagnostics in blood transfusion .....</b>	<b>501</b>
Molecular diagnostics for testing transfusion compatibility .....	501
Transmission of infections in blood transfusion .....	502
Molecular tests for screening of blood supply for viruses .....	502

Commercial molecular diagnostic technologies for blood screening .....	503
<i>Bridge amplification technology</i> .....	503
<i>COBAS AmpliScreen HCV and HIV Assays</i> .....	504
<i>INACTINE</i> .....	504
<i>NucliSens Extractor system</i> .....	504
<i>Pall's enhanced Bacteria Detection System</i> .....	505
<i>PCR combined with algorithm method</i> .....	505
<i>Prions detection in human blood</i> .....	505
<i>PRISM® automated system</i> .....	506
<i>Procleix HIV-1/HCV Assay</i> .....	506
<i>West Nile virus detection in human blood</i> .....	507
Advantages and limitations of molecular diagnostics for blood screening .....	507
<b>Molecular epidemiology .....</b>	<b>508</b>
Molecular epidemiology of genetic diseases .....	508
<i>Role of CNVs in study of genetic epidemiology</i> .....	509
<i>Accumulation of CNVs with aging</i> .....	509
<i>Monogenic versus polygenic disorders</i> .....	510
<i>Critical issues facing genetic epidemiology</i> .....	510
Molecular epidemiology of infectious diseases .....	510
<i>Methods and purposes</i> .....	510
<i>Emerging infections</i> .....	511
<i>Human vs. non-human infections</i> .....	512
<i>Genetics and susceptibility to infectious disease</i> .....	512
Molecular epidemiology of cancer .....	512
<i>Molecular epidemiology of p53 gene mutations</i> .....	513
<i>Molecular epidemiology of link between virus and cancer</i> .....	513
<i>Molecular epidemiology and cancer prevention</i> .....	513
<i>SNPs and molecular epidemiology</i> .....	514
<b>Molecular diagnostics for identification of food-borne pathogens .....</b>	<b>514</b>
Introduction .....	514
Molecular diagnostic methods used in food-borne infections .....	514
Limitations of use of molecular probes in food analysis .....	515
Detection of Listeria-contaminated foods .....	516
<i>Optical biosensor for detection of Listeria</i> .....	516
<i>Real-time PCR for detection of Listeria</i> .....	516
<i>Sequencing for investigation of food-borne Listeria infections</i> .....	517
Detection of Salmonella .....	517
<i>MicroSEQ® Salmonella Detection Kit</i> .....	517
E. Coli detection .....	517
<i>MicroSEQ® E. Coli Detection Kit</i> .....	517
<i>DuPont Bax system</i> .....	517
<i>MLG method for detection of multiple STEC strains</i> .....	518
<i>Detection of rare strains of E. Coli</i> .....	518
Companies with technologies for food pathogen detection .....	519
Transmissible spongiform encephalopathies (TSEs) .....	521
<i>Basis of molecular diagnosis of prion diseases</i> .....	521
<i>Molecular diagnosis of TSEs</i> .....	522
<i>Companies involved in developing molecular diagnostics for TSEs</i> .....	525
<b>Detection of genetically modified food .....</b>	<b>526</b>
<b>Molecular diagnostics for detection of doping in sports .....</b>	<b>527</b>
Screening of synthetic glucocorticosteroids in human urine .....	527
Detection of gene doping .....	528
<b>Role of molecular diagnostics in future healthcare .....</b>	<b>528</b>
Translation of genomic research into genetic testing for healthcare .....	528
Molecular diagnostics and disease management .....	529
Role of genetic biomarkers in disease management .....	529
Role of molecular diagnostics in personalized medicine .....	529
Integrated healthcare .....	530
<i>Screening</i> .....	530
<i>Early diagnosis</i> .....	530
<i>Prevention</i> .....	531
<i>Therapy based on molecular diagnosis</i> .....	531
<i>Monitoring of therapy</i> .....	531
<i>Advantages and limitations of integrated healthcare</i> .....	531
<i>Commercially available systems for integrated healthcare</i> .....	532
Combination of diagnostics and therapeutics .....	532
<i>Companion diagnostics</i> .....	532
<i>Companies involved in companion diagnostics</i> .....	533
Point-of-care diagnosis .....	534
<i>Advantages versus disadvantages of POC diagnosis</i> .....	536

<i>Technologies for point-of-care diagnosis</i> .....	536
<i>Biochips for POC diagnosis</i> .....	538
<i>CRISPR for POC diagnosis</i> .....	539
<i>Mobile detection of infections by microfluidic LAMP and smartphone</i> .....	540
<i>Nanosensors for POC diagnosis</i> .....	540
<i>POC Diagnostic Initiative</i> .....	540
<i>Paper-based POC diagnostic for infectious diseases</i> .....	541
<i>Synthetic biomarker-based POC diagnostic for cancer</i> .....	541
<i>Future prospects of POC testing</i> .....	541
<i>Companies developing POC diagnosis</i> .....	542
The impact of molecular diagnostics on clinical laboratory practice .....	544

## **10. Molecular Diagnostics in Forensic Medicine and Biological Warfare .. 547**

<b>Application of molecular diagnostics in forensic medicine</b> .....	<b>547</b>
Technologies .....	547
<i>ABO genotyping</i> .....	547
<i>DNA analysis for identification of ancient or historical specimens</i> .....	548
<i>DNA fingerprinting and short tandem repeats</i> .....	548
<i>DNA processing of forensic samples</i> .....	549
<i>DNA profiles from fingerprints</i> .....	549
<i>Fluorescent detection systems</i> .....	550
<i>Genome wide association studies linking genes to facial features</i> .....	550
<i>Mitochondrial DNA analysis</i> .....	550
<i>Next generation sequencing for forensic diagnosis</i> .....	551
<i>Pressure cycling technology for forensic applications</i> .....	552
<i>Polymorphic Alu insertions</i> .....	552
<i>SNP analysis</i> .....	552
Applications .....	552
<i>Applications in criminology</i> .....	553
<i>Identification of remains of military personnel</i> .....	554
<i>Identification of remains of victims of mass disasters</i> .....	554
<i>Parentage testing</i> .....	556
<i>Gender determination</i> .....	557
<i>Companies developing molecular diagnostics for forensic science</i> .....	557
<b>Molecular detection of biological warfare agents</b> .....	<b>558</b>
Introduction to biological warfare agents .....	558
Role of PCR in the diagnosis of biological warfare agents .....	559
<i>Multiplex PCR microarray assay to detect bioterror pathogens in blood</i> .....	560
Laboratory diagnosis of Anthrax .....	560
Challenges in diagnosis of biological warfare agents .....	561
US government efforts for detection of biological warfare agents .....	561
<i>The US Army Medical Research Institute of Infectious Diseases</i> .....	562
<i>Homeland Security Advance Research Projects Agency</i> .....	563
<i>Handheld Isothermal Silver Standard Sensor</i> .....	563
<i>Hapten mediated display and pairing of rAbs for biothreat assays</i> .....	563
Commercial development of diagnostic devices for biological agents .....	564
<i>Companies developing diagnostic devices for biological agents</i> .....	564
Various devices for testing .....	566
<i>Airborne bacterial spore detection technology</i> .....	566
<i>Analyte 2000 biosensor</i> .....	566
<i>Bead ARray Counter</i> .....	567
<i>Benchtop living cell biosensor</i> .....	567
<i>BioThreat Alert Test Strip</i> .....	567
<i>BioForce NanoArray sensor technology</i> .....	568
<i>Biodefense microarray</i> .....	568
<i>Biosensor based on mass spectrometry of microorganisms's RNA</i> .....	569
<i>Destruction and detection of anthrax by lysin</i> .....	569
<i>Hand-Held Advanced Nucleic Acid Analyzer</i> .....	569
<i>Identification of genetic markers of individual pathogens</i> .....	569
<i>Microbial Identification System based on OptiChip™</i> .....	570
<i>MicroChemLab</i> .....	570
<i>Nanode Array Sensor Microchips</i> .....	571
<i>ProteinChip-based detection of bioterrorism agents</i> .....	571
<i>QTL handheld biosensor</i> .....	571
<i>TIGER biosensor</i> .....	571
<i>The PathAlert™ Detection System</i> .....	572
<i>VereThreat™</i> .....	572
Concluding remarks about biodefense applications of diagnostics .....	572

## **11. References ..... 575**

## Tables

Table 1-1: Landmarks in development of molecular technology and its application to diagnosis .....	27
Table 1-2: Applications of molecular diagnostics .....	50
Table 2-1: Companies with products for nucleic acid isolation .....	60
Table 2-2: Applications of real-time PCR .....	69
Table 2-3: Some commercially available real-time PCR systems .....	72
Table 2-4: A selection of companies with commercially available FISH diagnostics .....	102
Table 2-5: Selected companies with RNA diagnostic tests .....	103
Table 2-6: Companies involved in whole genome amplification .....	113
Table 2-7: Companies involved in application of sequencing in molecular diagnostics .....	116
Table 2-8: Comparison of methods of identification of unknown DNA sequences .....	119
Table 2-9: Classification of methods of gene expression analysis .....	121
Table 2-10: A selection of companies with gene expression technologies .....	126
Table 2-11: Companies involved in developing PNA diagnostics .....	130
Table 2-12: Companies with bead-based diagnostic assay platforms .....	134
Table 2-13: Companies developing nucleic acid lateral flow molecular diagnostics.....	136
Table 3-1: Applications of biochip technology in relation to molecular diagnostics .....	139
Table 3-2: Companies developing whole genome chips/microarrays .....	145
Table 3-3: Companies involved in biochips for molecular diagnostics .....	146
Table 3-4: Companies developing microfluidic technologies.....	152
Table 3-5: Biosensor technologies with potential applications in molecular diagnostics .....	153
Table 3-6: Important applications of biosensors .....	163
Table 3-7: Companies involved in application of biosensors in molecular diagnostics .....	164
Table 3-8: Selected labels for nucleic acid detection.....	165
Table 3-9: Selected companies with fluorescence and chemiluminescence products .....	167
Table 3-10: Companies involved in molecular beacon manufacture and research .....	169
Table 3-11: Selected companies involved in molecular imaging .....	178
Table 3-12: Nanotechnologies with potential applications in molecular diagnostics .....	179
Table 3-13: Companies developing nanomolecular diagnostics .....	189
Table 4-1: Applications of protein biochips/microarrays .....	201
Table 4-2: Companies involved in developing diagnostic applications of protein biochips.....	208
Table 4-3: Disease-specific proteins in the cerebrospinal fluid of patients.....	211
Table 5-1: Mutation detection technologies .....	219
Table 5-2: Technologies for SNP analysis.....	227
Table 5-3: A sampling of companies involved in technologies for SNP genotyping .....	237
Table 5-4: Application of preimplantation genetic diagnosis in monogenic disorders .....	255
Table 5-5: Companies involved in prenatal/preimplantation diagnostics.....	256
Table 5-6: CFTR genotyping in cystic fibrosis – companies and technologies.....	258
Table 5-7: X-linked immunodeficiency disorders .....	262
Table 5-8: Available molecular diagnostics for neurogenetic diseases .....	270
Table 5-9: Companies offering genetic screening tests directly to consumers .....	279
Table 6-1: Genes that cause cardiovascular diseases .....	281
Table 6-2: Molecular diagnostics for cardiovascular diseases: commercial development.....	289
Table 7-1: Molecular techniques for the diagnosis of infections .....	291
Table 7-2: Commercially available molecular diagnostics for <i>sepsis</i> .....	301
Table 7-3: FDA-approved molecular diagnostics for various bacterial infections .....	310
Table 7-4: Commercially available molecular diagnostics for fungal infections .....	326
Table 7-5: FDA-approved molecular diagnostics for viral infections .....	330
Table 7-6: Companies with molecular diagnostics for influenza virus H1N1 .....	355
Table 7-7: Companies with molecular diagnostics for avian influenza virus H5N1 .....	360
Table 7-8: Commercially available molecular diagnostics for <i>C. difficile</i> .....	374
Table 7-9: Companies developing POC tests for the diagnosis of infections .....	379
Table 7-10: Selected companies involved in molecular diagnosis of infections .....	382
Table 8-1: Estimated new cases of cancer in the US of most involved organs - 2013.....	385
Table 8-2: Tumor suppressor genes, their chromosomal location, function, and associated tumors ...	387
Table 8-3: Viruses linked to human cancer .....	390
Table 8-4: A classification of molecular diagnostic methods in cancer .....	392
Table 8-5: Desirable characteristics of biomarkers for cancer .....	396
Table 8-6: Approved monoclonal antibodies for cancer diagnosis .....	406
Table 8-7: Methods for comparison of gene-expression profiling in tumor specimens .....	407
Table 8-8: Important cancer tests based on gene signatures.....	409
Table 8-9: Companies developing technologies for detection of CTCs .....	416
Table 8-10: Impact of in vivo molecular imaging of cancer on oncology practice.....	426
Table 8-11: Molecular diagnostic tests for breast cancer .....	435
Table 8-12: Companies developing cancer molecular diagnostics .....	480
Table 9-1: Applications of molecular diagnostics in the biopharmaceutical industry .....	485
Table 9-2: Molecular diagnostic technologies for drug discovery .....	486

Table 9-3: Molecular diagnostic technologies used for pharmacogenetic studies.....	486
Table 9-4: Companies with novel molecular toxicology technologies .....	487
Table 9-5: Applications of molecular diagnostics in gene therapy .....	492
Table 9-6: Companies involved in transplant molecular diagnostics.....	498
Table 9-7: Companies involved in molecular diagnostics of blood transfusions.....	503
Table 9-8: Pathogenic bacteria in food and targets for molecular diagnostic probes.....	515
Table 9-9: Companies involved in molecular diagnostics for food-borne infections .....	520
Table 9-10: Testing for harmful prions in brain tissue from dead cattle.....	522
Table 9-11: Companies involved in developing molecular diagnostics for TSEs .....	525
Table 9-12: Companies involved in detection of genetically modified food .....	526
Table 9-13: Companies involved in companion diagnostics.....	533
Table 9-14: Applications of point-of-care diagnosis .....	535
Table 9-15: Companies developing point-of-care diagnostic tests .....	542
Table 10-1: Forensic and legal applications of molecular diagnostics. ....	552
Table 10-2: Molecular technologies used for forensic applications .....	558
Table 10-3: Biological and chemical agents used as weapons of mass destruction.....	559
Table 10-4: Biological warfare agents that can be identified by PCR methods .....	559
Table 10-5: Companies developing devices for detection of biological warfare agents.....	564

## Figures

Figure 1-1: Relation of molecular diagnostics to other technologies.....	51
Figure 2-1: MNazyme qPCR .....	74
Figure 2-2: Rolling circle amplification technology .....	84
Figure 2-3: A schematic view of the Invader operating system .....	92
Figure 2-4: Principle of fluorescent in situ hybridization .....	97
Figure 2-5: Repli-G system of QIAGEN .....	114
Figure 2-6: DNA sequencing process .....	115
Figure 2-7: Electrochemical detection of DNA .....	133
Figure 2-8: Elements of a Scorpions primer .....	135
Figure 3-1: Affymetrix GeneChip technology .....	140
Figure 3-2: Basic principle of a biosensor.....	153
Figure 3-3: Surface plasmon resonance (SPR) technology.....	158
Figure 7-1: Use of DNA chips in diagnosing microbial infections .....	294
Figure 7-2: High throughput DNA pyrosequencing for pathogen discovery .....	300
Figure 9-1: The mechanism of SHERLOCK for POC diagnosis .....	539